BEDMINSTER, N.J.--(BUSINESS WIRE)--Mar. 27, 2012--
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 11th
Annual Needham Healthcare Conference in New York on Tuesday, April 3,
2012 at 8:40 a.m. ET. The presentation will be available as a live
webcast with a replay available approximately three hours after the
presentation has concluded. Interested parties may access the webcast
from the investors’ calendar of events page on the NPS website at http://www.npsp.com.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing
orphan products to patients with rare disorders and few, if any,
therapeutic options. NPS is advancing two late-stage registration
programs. A New Drug Application is undergoing FDA review for Gattex®
(teduglutide) as a treatment for adult short bowel syndrome (SBS) and a
Phase 3 registration study has been completed for Natpara™ (recombinant
human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism.
NPS’ earlier stage pipeline includes two calcilytic compounds, NPSP790
and NPSP795, with potential application in rare disorders involving
increased calcium receptor activity, such as autosomal dominant
hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary
programs with a royalty-based portfolio of products and product
candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa
Hakko Kirin, Nycomed, and Janssen Pharmaceuticals, Inc.
Source: NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
